{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T01:16:53Z","timestamp":1775697413080,"version":"3.50.1"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective of this study was to assess the risk of arterial thrombosis in patients who harbor the JAK2V617F allele burden \u22651% detected during workup for myeloproliferative neoplasms (MPNs). We conducted a large cross-sectional analysis consisted of 5,220 patients who were tested for JAK2V617F and 1,047,258 people matched in age from health care insurance provider, taking into account age, sex, hypertension, diabetes, atrial fibrillation. Compared with noncarriers, mutation carriers were older, less likely to be current or past smokers and had lower body mass index. There was no significant difference between the groups regarding myocardial infarction and peripheral vascular disease. However, JAK2V617F \u22651% at age 34 to 54 years was associated with eightfold more likely to have transient ischemic attack (TIA)\/stroke history unrelated to hypertension, diabetes, or atrial fibrillation. Association of JAK2V617F with TIA\/stroke was also observed in the older age group, albeit a weaker association and not statistically significant. Prevalence of TIA\/stroke was higher in patients with JAK2V617F negative, with odds ratio of 3.93 when compared with the general population after confounder adjustments. Further research is warranted to verify the relation between allele burden of JAK2V617F mutation and TIA\/stroke and the role of JAK2V617F per se as a risk factor for arterial thrombosis in the absence of overt MPN. Also, consideration should be paid to the screened group with JAK2V617F negative due to the high incidence of TIA\/stroke among them in comparison to the general population.<\/jats:p>","DOI":"10.1055\/s-0042-1743470","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:03:33Z","timestamp":1647302613000},"page":"1333-1340","source":"Crossref","is-referenced-by-count":5,"title":["JAK2V617F Is a Risk Factor for TIA\/Stroke in Young Patients"],"prefix":"10.1055","volume":"122","author":[{"given":"Tamar","family":"Shapira Cohen","sequence":"additional","affiliation":[{"name":"Institute of Medical Genetics, Maccabi HMO, Rehovot, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[{"name":"Maccabitech, Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Department of Statistics and Operations Research, Faculty of Exact Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehud","family":"Grossman","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Division of Internal Medicine, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mordechai","family":"Shohat","sequence":"additional","affiliation":[{"name":"Institute of Medical Genetics, Maccabi HMO, Rehovot, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Cancer Research Center, Wohl Institute of Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ophira","family":"Salomon","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Thrombosis Unit, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2\u2009V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population","volume":"160","author":"C Nielsen","year":"2013","journal-title":"Br J Haematol"},{"issue":"23","key":"ref2","doi-asserted-by":"crossref","first-page":"37239","DOI":"10.18632\/oncotarget.16744","article-title":"The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study","volume":"8","author":"M Perricone","year":"2017","journal-title":"Oncotarget"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"A Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3390\/cells8080854","article-title":"Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation","volume":"8","author":"F Perner","year":"2019","journal-title":"Cells"},{"issue":"08","key":"ref5","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2016-07-726448","article-title":"JAK2\u2009V617F clonal disorders: fate or chance?","volume":"128","author":"G S Vassiliou","year":"2016","journal-title":"Blood"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"D P Steensma","year":"2015","journal-title":"Blood"},{"issue":"25","key":"ref7","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis","volume":"120","author":"J H Smalberg","year":"2012","journal-title":"Blood"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","article-title":"Incidence of the JAK2\u2009V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders","volume":"5","author":"V De Stefano","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4065\/83.4.457","article-title":"JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients","volume":"83","author":"A Pardanani","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"M Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12075","article-title":"Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2\u2009V617F and other relevant mutations","volume":"160","author":"A J Bench","year":"2013","journal-title":"Br J Haematol"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders","volume":"107","author":"F Passamonti","year":"2006","journal-title":"Blood"},{"issue":"26","key":"ref13","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"T Barbui","year":"2012","journal-title":"Blood"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.24607","article-title":"Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"A Tefferi","year":"2017","journal-title":"Am J Hematol"},{"issue":"S 02","key":"ref15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF03165140","article-title":"What is the standard treatment in essential thrombocythemia","volume":"76","author":"T Barbui","year":"2002","journal-title":"Int J Hematol"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11239-020-02175-8","article-title":"Ph- myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide","volume":"51","author":"M Ko\u0161\u0165\u00e1l","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"116990","DOI":"10.1016\/j.jns.2020.116990","article-title":"Clinical characteristics and brain MRI findings in myeloproliferative neoplasms","volume":"416","author":"K Nagai","year":"2020","journal-title":"J Neurol Sci"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F promotes venous thrombosis through \u03b21\/\u03b22 integrin activation","volume":"128","author":"B Edelmann","year":"2018","journal-title":"J Clin Invest"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1055\/s-0038-1667015","article-title":"Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features","volume":"118","author":"A Guadall","year":"2018","journal-title":"Thromb Haemost"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"A Guy","year":"2019","journal-title":"Haematologica"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"714943","DOI":"10.3389\/fimmu.2021.714943","article-title":"Janus Kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2\/STAT3 pathway inhibition","volume":"12","author":"H Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4065\/83.4.398","article-title":"Thrombophilia screening: little role for the JAK2V617F mutation","volume":"83","author":"M Mannucci","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3324\/haematol.10358","article-title":"The V617F mutation of JAK2 is very uncommon in patients with thrombosis","volume":"92","author":"A F Remacha","year":"2007","journal-title":"Haematologica"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11739-011-0634-3","article-title":"Polycythemia vera: gender-related phenotype differences","volume":"7","author":"R Landolfi","year":"2012","journal-title":"Intern Emerg Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"T Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/th15-04-0326","article-title":"Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment","volume":"115","author":"V De Stefano","year":"2016","journal-title":"Thromb Haemost"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"874146","DOI":"10.1155\/2011\/874146","article-title":"Gender and vascular complications in the JAK2\u2009V617F-positive myeloproliferative neoplasms","volume":"2011","author":"B L Stein","year":"2011","journal-title":"Thrombosis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.1365-2141.2002.03750.x","article-title":"Sex ratios and the risks of haematological malignancies","volume":"118","author":"R A Cartwright","year":"2002","journal-title":"Br J Haematol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.thromres.2011.03.024","article-title":"Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis","volume":"128","author":"D Colaizzo","year":"2011","journal-title":"Thromb Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","article-title":"Polycythemia vera: historical oversights, diagnostic details, and therapeutic views","volume":"35","author":"A Tefferi","year":"2021","journal-title":"Leukemia"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"A Carobbio","year":"2009","journal-title":"Exp Hematol"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1743470.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T23:20:38Z","timestamp":1661124038000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1743470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":31,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2022,8,21]]},"published-print":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1743470","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]}}}